Literature DB >> 3344743

The long-term outcome of hepatitis B infection in hemodialysis patients.

J D Harnett1, P S Parfrey, M Kennedy, J B Zeldis, T I Steinman, R D Guttmann.   

Abstract

Little information on the long-term outcome of hepatitis B virus (HBV) infection in hemodialysis patients is available. We studied 49 hemodialysis patients, seen at three centers between 1969 and 1985, who developed HBV infection. Patients were studied retrospectively and followed for up to 10 years (mean 52 +/- 5 months). Only 20% (n = 10) of patients converted to hepatitis B surface antigen (HBsAg) negative, the majority of whom did so within 6 months of becoming HBsAg positive. Twenty-nine percent (n = 14) of patients developed chronic elevation of liver enzymes which remitted in one patient. Only one patient died from liver disease. We conclude that HBV infection in hemodialysis patients more often results in persistent antigenemia and chronic elevation of liver enzymes than is the case in patients without kidney disease. However, the risk of death from liver disease is low.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3344743     DOI: 10.1016/s0272-6386(88)80151-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  9 in total

Review 1.  Chronic viral hepatitis in kidney transplantation.

Authors:  Janna Huskey; Alexander C Wiseman
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

2.  Infections in hemodialysis: a concise review. Part II: blood transmitted viral infections.

Authors:  T Eleftheriadis; V Liakopoulos; K Leivaditis; G Antoniadi; I Stefanidis
Journal:  Hippokratia       Date:  2011-04       Impact factor: 0.471

Review 3.  Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

4.  Therapy for HBV Infection in Hemodialysis Patients: Is it Possible?

Authors:  Behzad Einollahi
Journal:  Hepat Mon       Date:  2012-03-28       Impact factor: 0.660

5.  A randomized pilot trial on the effect of granulocyte-colony stimulating factor on antibody response in hemodialysis patients who had not responded to routine hepatitis B virus vaccine.

Authors:  Jamshid Roozbeh; Kamran Bagheri-Lankarani; Poopak Mohaghegh; Ghanbarali Raeesjalali; Saeed Behzadi; Mehdi Sagheb; Mehrdad Vossoughi; Bahar Bastani
Journal:  J Nephropathol       Date:  2015-01-01

6.  Circulating Interferon-λ3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients.

Authors:  Alicja E Grzegorzewska; Monika K Świderska; Adrianna Mostowska; Paweł P Jagodziński
Journal:  Biomed Res Int       Date:  2017-10-31       Impact factor: 3.411

Review 7.  Virus-Associated Nephropathies: A Narrative Review.

Authors:  Christophe Masset; Paul Le Turnier; Céline Bressollette-Bodin; Karine Renaudin; François Raffi; Jacques Dantal
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

8.  Differential Effect of Viral Hepatitis Infection on Mortality among Korean Maintenance Dialysis Patients: A Prospective Multicenter Cohort Study.

Authors:  Eugene Kwon; Jang-Hee Cho; Hye Min Jang; Yon Su Kim; Shin-Wook Kang; Chul Woo Yang; Nam-Ho Kim; Hyun-Ji Kim; Jeung-Min Park; Ji-Eun Lee; Hee-Yeon Jung; Ji-Young Choi; Sun-Hee Park; Chan-Duck Kim; Yong-Lim Kim
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

Review 9.  Oncogenic mechanisms in renal insufficiency.

Authors:  Simona Ruxandra Volovat; Constantin Volovat; Ingrith Miron; Mehmet Kanbay; David Goldsmith; Cristian Lungulescu; Silvia Corina Badarau; Adrian Covic
Journal:  Clin Kidney J       Date:  2020-10-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.